Followers | 39 |
Posts | 2870 |
Boards Moderated | 0 |
Alias Born | 12/06/2003 |
Sunday, November 19, 2017 3:23:12 PM
Like mice are similar to elephants in that both have 4 legs, UHD?
Please try forgive the sarcasm. I am quite well aware of the plain fact few investors in scientific R&D know or care much about the science with that being particularly true of shorts.
Aside from VBIV's glioblastoma cancer vaccine with dim prospects in my unresearched opinion, the pair are not remotely like the Israeli biotech hoping to find a cure [cure, not treatment] for nonsense diseases like the many varieties of muscular dystrophy.
All nonsense diseases [name derived from antisense lingo that is a classification of catastrophic diseases resulting from incomplete DNA] are very rare but I think cystic fibrosis is the most common and most devastating, maybe because of a cousin in Ireland who had the disease.
Ignoring my own bias, surely any sentient beings interested in news of even the tabloid variety would have had trouble missing the excitement caused by a dubious treatment for a single variety of muscular dystrophy.
Well yeah, but will Eloxx, the new Sevion if all goes according to plan, cure any nonsense diseases?
- Most likely not given grim statistical odds but the odds themselves are dubious in such a case.
Just some dull thoughts for you more thrilled by chewing the rag.
Best, Terry
Recent ELOX News
- Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:02:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/29/2024 08:11:23 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 03/21/2024 06:20:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/14/2024 08:30:38 PM
- Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases • GlobeNewswire Inc. • 03/13/2024 03:42:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/25/2024 02:44:31 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/24/2024 10:11:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:10:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:11:02 PM
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:26:20 PM
- Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria • GlobeNewswire Inc. • 10/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:43 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/20/2023 05:26:02 PM
- Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 09/19/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:05:57 PM
- Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2023 09:15:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 02:14:41 PM
- Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013 • GlobeNewswire Inc. • 09/07/2023 01:00:52 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM